Prelude Therapeutics (PRLD)
Develops small-molecule oncology programs centered on JAK2V617F inhibition and KAT6A degradation.
$4.27
vs last close−0.58 (−11.96%)
Something off on this page? Send us feedback.
Next report
Nov 11, 26
in 49 days
EPS estimate
−$0.16
Revenue estimate
$27.7M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.38−$0.42−$0.41−$0.26−$0.20−$0.13−$0.14Pending
Estimate−$0.48−$0.47−$0.45−$0.35−$0.33−$0.27−$0.20−$0.16
Surprise+20.8%+10.6%+8.9%+25.7%+39.4%+51.9%+28.8%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$4.0M——$6.5M$5.6M$4.6M$5.7MPending
Estimate———$20.5M$20.5M$4.6M$5.7M$27.7M
Surprise———−68.3%−72.7%0.0%0.0%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | −$0.35 | — | — |
| Sep 2028 | −$0.34 | — | — |
| Jun 2028 | −$0.35 | — | — |
| Mar 2028 | −$0.34 | — | — |
| Dec 2027 | −$0.25 | — | — |
| Sep 2027 | −$0.21 | — | — |
| Jun 2027 | −$0.16 | — | — |
| Mar 2027 | −$0.18 | — | — |
| Dec 2026 | −$0.18 | — | — |
| Nov 2026 | −$0.16 | — | — |
| Aug 2026 | −$0.20 | −$0.14 | +28.8% |
| May 2026 | −$0.27 | −$0.13 | +51.9% |
| Mar 2026 | −$0.33 | −$0.20 | +39.4% |
| Nov 2025 | −$0.35 | −$0.26 | +25.7% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | −$0.35 | — | — | $8.7M | — | — | — |
| Sep 2028 | −$0.34 | — | — | $8.3M | — | — | — |
| Jun 2028 | −$0.35 | — | — | $8.0M | — | — | — |
| Mar 2028 | −$0.34 | — | — | $7.7M | — | — | — |
| Dec 2027 | −$0.25 | — | — | $6.2M | — | — | — |
| Sep 2027 | −$0.21 | — | — | $2.7M | — | — | — |
| Jun 2027 | −$0.16 | — | — | $6.0M | — | — | — |
| Mar 2027 | −$0.18 | — | — | $5.4M | — | — | — |
| Dec 2026 | −$0.18 | — | — | $2.7M | — | — | — |
| Nov 11, 2026 | −$0.16 | — | — | $27.7M | — | — | — |
| Aug 11, 2026 | −$0.20 | −$0.14 | +28.8% | $5.7M | $5.7M | 0.0% | +10.1% |
| May 12, 2026 | −$0.27 | −$0.13 | +51.9% | $4.6M | $4.6M | 0.0% | −3.3% |
| Mar 10, 2026 | −$0.33 | −$0.20 | +39.4% | $20.5M | $5.6M | −72.7% | +16.5% |
| Nov 12, 2025 | −$0.35 | −$0.26 | +25.7% | $20.5M | $6.5M | −68.3% | +8.9% |
| Aug 14, 2025 | |||||||
| May 6, 2025 | |||||||
| Mar 10, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 12, 2024 | |||||||
| May 7, 2024 | |||||||
| Feb 15, 2024 | |||||||
| Nov 1, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 8, 2023 | |||||||
| Mar 15, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Aug 9, 2022 | |||||||
| May 10, 2022 | |||||||
| Mar 16, 2022 | |||||||
| Nov 12, 2021 | |||||||
| Aug 12, 2021 | |||||||
| May 11, 2021 | |||||||
| Mar 16, 2021 | |||||||
| Nov 10, 2020 | |||||||
| Sep 25, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Mar 31, 2019 |